The Chalcogen, X, Is In A -c(=x)- Group Patents (Class 548/204)
-
Publication number: 20120328569Abstract: Disclosed are compounds of formula (I) that are used as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.Type: ApplicationFiled: March 2, 2011Publication date: December 27, 2012Inventors: Casey Cameron McComas, Nigel J. Liverton, Richard Soll, Peng Li, Xuanjia Peng, Hao Wu, Frank Narjes, Joerg Habermann, Uwe Koch, Shilan Liu
-
Publication number: 20120329841Abstract: Treatment of cancer includes administering a compound of formula I, for example desritonavir, to a subject. In particular, treatment of breast cancer is described.Type: ApplicationFiled: February 17, 2009Publication date: December 27, 2012Inventors: David A. Potter, Monica Milani, Anjaiah Srirangam, Ranjana Mitra, Rory P. Remmel
-
Publication number: 20120329787Abstract: Disclosed are compounds of Formula 1, including all geometric and stereoisomers, tautomers, N-oxides, and salts thereof, wherein Q, Z, R2, R3 and R4 are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.Type: ApplicationFiled: June 22, 2011Publication date: December 27, 2012Applicant: E.I. DU PONT DE NEMOURS AND COMPANYInventor: THOMAS MARTIN STEVENSON
-
Patent number: 8338616Abstract: The present invention relates to a composition of a thiazolium compound of formula I or a solvate thereof, wherein the definitions of groups in the formula I are as those given in the claims:Type: GrantFiled: September 15, 2009Date of Patent: December 25, 2012Assignee: Beijing Molecule Science And Technology Co., Ltd.Inventors: Song Li, Wu Zhong, Lili Wang, Zhibing Zheng, Hao Cui, Junhai Xiao, Gang Cheng, Yunde Xie, Bing Zhang
-
Publication number: 20120323000Abstract: The present invention relates generally to olefin metathesis. In some embodiments, the present invention provides methods for Z-selective ring-closing metathesis.Type: ApplicationFiled: June 1, 2012Publication date: December 20, 2012Applicants: TRUSTEES OF BOSTON COLLEGE, MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Amir H. Hoveyda, Miao Yu, Chenbo Wang, Richard R. Schrock
-
Publication number: 20120322795Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, C, R1a, R1b, R2, R3, R4a and R4b are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.Type: ApplicationFiled: December 14, 2011Publication date: December 20, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Angela BERRY, Zhidong CHEN, Stephane DE LOMBAERT, Michel Jose EMMANUEL, Pui Leng LOKE, Chuk Chui MAN, Tina Marie MORWICK, Hidenori TAKAHASHI
-
Publication number: 20120322838Abstract: Epothilone compounds represented by formula (I), their preparation methods and their use for preparing medicines are disclosed. The epothilone compounds are prepared by bioconversion and chemosynthesis or chemical modifications using epothilones or their derivatives as starting materials. Said epothilone compounds can be sued to treat proliferative diseases.Type: ApplicationFiled: June 18, 2012Publication date: December 20, 2012Inventors: Li Tang, Rongguo Qiu
-
Publication number: 20120321622Abstract: The present invention relates to novel thiazole-substituted indolin-2-ones as inhibitors of CSCPK and related kinases; to methods of inhibiting cancer stem cells by using a kinase inhibitor; to pharmaceutical compositions containing such compounds; and to methods of using such compounds in the treatment of a protein kinase related disorder in a mammal; and to processes of making such compounds and intermediates thereof.Type: ApplicationFiled: August 27, 2012Publication date: December 20, 2012Applicant: Boston Biomedical, Inc.Inventors: Chiang Jia Li, Ji-Feng Liu, Youzhi Li, Wei Li, Harry Rogoff
-
Publication number: 20120316348Abstract: The present invention provides compounds of formula (I): as described generally and in classes and subclasses herein. The present invention additionally provides pharmaceutical compositions comprising compounds of formula (I) and provides methods of treating cancer comprising administering a compound of formula (I).Type: ApplicationFiled: February 7, 2012Publication date: December 13, 2012Inventors: Samuel J. Danishefsky, Alexey Rivkin, Yoshimura Fumikiko, Ting-Chao Chou, Ana E. Gabarda, Huajin Dong
-
Publication number: 20120316148Abstract: The invention relates to compounds and methods for modulating one or more components of a kinase signaling cascade.Type: ApplicationFiled: June 7, 2012Publication date: December 13, 2012Applicant: Dynamix Pharmaceuticals LTD.Inventors: Oren M. Becker, Itai Bloch, Efrat Ben-Zeev, Alina Shitrit, Avihai Yacovan, Sharon Gazal, Vered Behar, Alexander Konson, Nili Schutz, Sima Mirilashvili, Gali Golan
-
Publication number: 20120309762Abstract: The present invention features compounds of formula I or pharmaceutically acceptable salts, solvates or prodrugs thereof, and methods of using the same to inhibit the metabolizing activities of CYP enzymes. The present invention also features methods of using these compounds, salts, solvates or prodrugs to improve the pharmacokinetics of drugs that are metabolized by CYP enzymes.Type: ApplicationFiled: August 16, 2012Publication date: December 6, 2012Applicant: Abbott LaboratoriesInventors: Larry L. Klein, Hui-Ju Chen, Ming C. Yeung, Charles A. Flentge, John T. Randolph, Peggy P. Huang, Douglas K. Hutchinson, Dale J. Kempf
-
Patent number: 8318949Abstract: The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.Type: GrantFiled: September 21, 2011Date of Patent: November 27, 2012Assignee: Novartis AGInventors: Sultan Chowdhury, Natalie Dales, Julia Fonarev, Jianmin Fu, Duanjie Hou, Qi Jia, Vishnumurthy Kodumuru, Natalia Pokrovskaia, Shaoyi Sun, Zaihui Zhang
-
Publication number: 20120295894Abstract: Described herein are novel beta-secretase inhibitors and methods for their use, including methods of treating Alzheimer's disease.Type: ApplicationFiled: December 1, 2011Publication date: November 22, 2012Inventors: Geoffrey M. BILCER, Thippeswamy Devasamudram, Sudha V. Ankala, John C. Lilly, Chunfeng Liu, Hui Lei, Arun K. Ghosh, Makoto Inoue
-
Publication number: 20120295920Abstract: HIV inhibitors of formula wherein R1 is halo, C1-4alkoxy, trifluoromethoxy; n is 0 or 1; A is CH or N; R5 and R6 are hydrogen, C1-4alkyl, halo; R7 and R8 are C1-4alkyl or C1-4alkoxyC1-4alkyl; R9 is C1-4alkyl, cyclopropyl, trifluoromethyl, C1-4alkoxy, or dimethylamino; R10 is hydrogen, C1-4alkyl, cyclopropyl, trifluoromethyl, C1-4alkoxy, or dimethylamino; pharmaceutically acceptable addition salts and solvates thereof; pharmaceutical compositions containing these compounds as active ingredient and processes for preparing said compounds.Type: ApplicationFiled: December 10, 2010Publication date: November 22, 2012Inventors: Genadiy Kalayanov, Bart Rudolf Romanie Kesteleyn, Kevin Parkes, Bengt Bertil Samuelsson, Wim Bert Griet Schepens, Johannes Wilhelmus J. Thuring, Hans Kristian Wallberg, Jörg Kurt Wegner
-
Publication number: 20120295909Abstract: The invention relates to compounds corresponding to the general formula (I): in which R2 represents a hydrogen, fluorine, hydroxyl, cyano, trifluoromethyl, C1-6-alkyl, C1-6-alkoxy or —NR8R9; n and m represent, independently of one another, an integer equal to 1, 2 or 3, it being understood that the sum m+n is at most equal to 5; A represents a covalent bond, an oxygen, a C1-6-alkylene or —O—C1-6-alkylene; R1 represents a phenyl or a heterocycle which is optionally substituted; R3 represents a hydrogen, fluorine, C1-6-alkyl or trifluoromethyl; R4 represents an optionally substituted 5-membered heterocycle; in the form of the base or of an addition salt with an acid; with the exclusion of 5-methylisoxazol-3-ylmethyl 4-hydroxy-4-(4-chlorophenyl)piperidine-1-carboxylate. The invention also relates to a process for the preparation of the compounds of formula (I), to compositions comprising them and to their therapeutic application.Type: ApplicationFiled: January 19, 2011Publication date: November 22, 2012Applicant: SANOFIInventors: Ahmed Abouabdellah, Antoine Ravet
-
Publication number: 20120295923Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.Type: ApplicationFiled: January 19, 2011Publication date: November 22, 2012Inventors: Christopher William Am Ende, Benjamin Adam Fish, Douglas Scott Johnson, Ricardo Lira, Christopher John O'Donnell, Martin Youngjin Pettersson, Corey Michael Stiff
-
Publication number: 20120289554Abstract: This invention relates to novel 4-dimethylaminobutyric acid derivatives of the formula wherein A1, A2, R1, m and n are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds inhibit carnitine palmitoyl transferase (CPT) activity, in particular CPT2 activity, and can be used as medicaments in methods for the treatment of diseases modulated by CPT2 inhibitors.Type: ApplicationFiled: July 24, 2012Publication date: November 15, 2012Inventors: Mirjana Andjelkovic, Simona M. Ceccarelli, Odile Chomienne, Gerald Lewis Kaplan, Patrizio Mattei, Jefferson Wright Tilley
-
Publication number: 20120283248Abstract: Compounds having inverse agonist functional selectivity for GABAA receptors containing the ?5 subunit for use as a medicament in the treatment of cognitive impairments in subjects suffering from Down syndrome. The use of these compounds is disclosed. Pharmaceutical compositions for such treatment can comprise these compounds or suitable pharmaceutically acceptable salt thereof, a polyethoxylated castor oil and dimethyl sulfoxide (DMSO). Methods are disclosed for enhancing cognitive function, or treating or lessening the severity of cognitive impairments, in subjects suffering from Down syndrome by administering to a subject in need thereof a pharmaceutically effective amount of one or more of these compounds.Type: ApplicationFiled: August 24, 2010Publication date: November 8, 2012Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRSInventors: Marie-Claude Potier, Robert Dodd, Benoît Delatour, Jérôme Braudeau, Yann Herault
-
Publication number: 20120277223Abstract: The present invention relates to compounds of formula (I): wherein Q, G1, G2, and G3, are defined herein. Pharmaceutical compositions and methods for treating DGAT-1 related diseases or conditions are also disclosed.Type: ApplicationFiled: July 16, 2012Publication date: November 1, 2012Inventors: Andrew S. Judd, Mathew M. Mulhern, Rajesh R. lyengar, Philip R. Kym, Andrew J. Souers
-
Publication number: 20120277274Abstract: The present application relates to compositions for parenteral administration of epothilone compounds, such as ixabepilone.Type: ApplicationFiled: January 3, 2012Publication date: November 1, 2012Inventors: Chandrasekhar Kocherlakota, Tarun Singh, Nagaraju Banda, Prasad Vure, Aparna Mulupuru
-
Patent number: 8299266Abstract: A process for making aziridinyl epothilone compounds according to formula G, starting from a compound according formula C where R1, R2, R3, R4, R5, R6, R12, R13, Z1 and Z2 in formulae (G) and (C) are as defined herein. The aziridinyl epothilone compounds of formula (G) are useful for the treatment of cancer.Type: GrantFiled: February 21, 2012Date of Patent: October 30, 2012Assignee: Bristol-Myers Squibb CompanyInventors: Luca Parlanti, Jurong Yu
-
Patent number: 8299267Abstract: The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease.Type: GrantFiled: September 24, 2008Date of Patent: October 30, 2012Assignees: CoMentis, Inc., Purdue Research FoundationInventors: Arun K. Ghosh, Chunfeng Liu, Thippeswamy Devasamudram, Hui Lei, Lisa M. Swanson, Sudha V. Ankala, John C. Lilly, Geoffrey M. Bilcer
-
Publication number: 20120264793Abstract: The present invention discloses the pharmaceutical use of a 2?,2-bis-thiazole non-nucleoside compound of formula I as an inhibitor of hepatitis C virus (HCV). The 2?,2-bis-thiazole non-nucleoside compound can inhibit the replication of HCV, and thus has an anti-HCV activity and is useful for treating hepatitis C.Type: ApplicationFiled: November 24, 2010Publication date: October 18, 2012Applicant: Shanghai Institute of Materia Medica, Chinese Academy of SciencesInventors: Fajun Nan, Jianping Zuo, Yangming Zhang, Feihong Ji, Haijun Chen, Xiankun Tong
-
Publication number: 20120258990Abstract: The present invention relates to heterocyclic compounds of formula (I) which have microbiocidal activity, in particular fungicidal activity: formula (I) wherein G1 and G2 are independently O or S; T is —C(R9R10)—, —C(R11)?C(R12)—, —C?C—, NR13 or O; Y1 and Y2 are independently CR14 or N; Q is —C(?O)—N(R15)-z, —C(?S)—N(R16)-z, —C(?O)—O-z, —N(R17)—C(?O)-z, —N(R18)—C(?S)-z, —N(R19)—C(?O)—O-z or —N(R20)—C(?O)—N(R21)-z, in each case z indicates the bond that is connected to R8; n is 1, 2, 3 or 4 when T is —C(R9R10)—, NR13 or O; n is 1, 2, 3 when T is —C(R11)?C(R12)— or —C?C—; R1, R2, R3, R4, R11, R12 and R14 each independently are hydrogen, halogen, cyano, C1-C4alkyl, or C1-C4haloalkyl; R5, R13, R15, R16, R17, R18, R19, R20 and R21 each independently are hydrogen, C1-C4alkyl or C1-C4alkoxy; R6 and R7 each independently are hydrogen, halogen, cyano, hydroxy, C1-C4alkyl, C1-C4alkoxy, C1-C4alkylthio, C1-C4haloalkyl, C1-C4haloalkoxy, C1-C4haloalkylthio or together from a carbonyl group (?O); R9 and R10 each independentType: ApplicationFiled: November 25, 2010Publication date: October 11, 2012Applicant: SYNGENTA CROP PROTECTION, LLCInventors: Sarah Sulzer, Clemens Lamberth
-
Publication number: 20120258963Abstract: The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of ?3-adrenoceptor.Type: ApplicationFiled: June 20, 2012Publication date: October 11, 2012Inventors: Richard Berger, Lehua Chang, Scott D. Edmondson, Stephen D. Goble, Sookhee Nicole Ha, Nam Fung Kar, Ihor E. Kopka, Bing Li, Gregori J. Morriello, Chris R. Moyes, Dong-Ming Shen, Liping Wang, Cheng Zhu
-
Publication number: 20120252792Abstract: The invention provides methods, compositions, and kits for the inhibition of members of the Rho GTPase family. Specifically, the invention provides methods, compositions and kits for the inhibition of RhoA and/or RhoC transcriptional signalling. The invention finds use in treatment of Rho-mediated disease states (e.g., tumor metastasis, inflammation, inflammatory disease), Rho-mediated biological conditions, and in cell signaling research.Type: ApplicationFiled: September 17, 2010Publication date: October 4, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Richard Neubig, Chris Evelyn, Jenny Ryu, Scott Larsen, Jessica Bell
-
Patent number: 8278290Abstract: The present invention relates to compounds of general formula (I) as tublin polymerization inhibitors and methods for preparing such compounds.Type: GrantFiled: February 14, 2006Date of Patent: October 2, 2012Assignee: Biononics LimitedInventors: Jason Hugh Chaplin, Gurmit Singh Gill, Damian Wojciech Grobelny, Bernard Luke Flynn
-
Publication number: 20120232284Abstract: A new crystalline polymorph of ritonavir and methods for its use and preparation are disclosed.Type: ApplicationFiled: May 25, 2012Publication date: September 13, 2012Applicant: ABBOTT LABORATORIESInventors: John F. Bauer, Azita Saleki-Gerhardt, Bikshandarkoil A. Narayanan, Sanjay R. Chemburkar, Ketan M. Patel, Harry O. Spiwek, Philip E. Bauer, Kimberly A. Allen
-
Patent number: 8263044Abstract: The present invention relates to novel stilbene like compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof. The present invention more particularly provides novel stilbene like compounds of the general formula (I). Also included is a method for treatment of cancer, psoriasis, proliferative conditions and conditions mediated by HDAC, in a mammal comprising administering an effective amount of a novel compound of formula (I) as described above.Type: GrantFiled: November 6, 2006Date of Patent: September 11, 2012Assignee: Orchid Research Laboratories LimitedInventors: Akella Satya Surya Visweswara Srinivas, Urkalan Kaveri Balan, Narayana Swamy Punthalir, Rama Swamy Velmurugan, Sriram Rajagopal, Gaddam Om Reddy, Virendra Kachhadia
-
Publication number: 20120226049Abstract: A method for producing 5-(aminomethyl)-2-chlorothiazole, which comprises the step of mixing a compound represented by formula (2): a mineral acid and a nitrite salt together.Type: ApplicationFiled: November 29, 2010Publication date: September 6, 2012Inventor: Kazuyuki Yamagata
-
Patent number: 8258311Abstract: The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-?) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-?) inhibitors, and to methods for regulating angiogenesis.Type: GrantFiled: November 23, 2009Date of Patent: September 4, 2012Assignee: Aerpio Therapeutics Inc.Inventors: Jeffrey Lyle Gray, Kande K. D. Amarasinghe, Cynthia Monesa Clark, Ryan Matthew Nichols, Matthew B. Maier
-
Publication number: 20120220520Abstract: The present invention relates to the combination comprising an HCV NS3/4a protease inhibitor and a compound of formula (II). The combination is useful to improve the bioavailability of the HCV NS3/4a protease inhibitor. As such, the combination is useful for treating conditions associated with the Hepatitis C virus in patients. Pharmaceutical compositions and kits comprising this combination, and processes for preparing the combination and the pharmaceutical formulations are also provided.Type: ApplicationFiled: January 26, 2007Publication date: August 30, 2012Inventors: Gerben Albert Eleutherius Van't Klooster, Herman Augustinus De Kock, Pierre Jean-Marie Bernard Raboisson, Christel Florentina E. Van Den Eynde
-
Publication number: 20120214804Abstract: The present invention relates to a pharmaceutical composition comprising a compound of formula (1), (2) or (3) as defined in the specification for the prevention or treatment of diseases associated with oxidative stress, mitochondria dysfunction, hypoxic injury, necrosis and/or ischemic reperfusion injury, and a cosmetic composition comprising an indole compound having an antioxidant effect.Type: ApplicationFiled: October 25, 2010Publication date: August 23, 2012Inventors: Soon Ha Kim, Hyoung Jin Kim, Heui Sul Park, Seon Yeong Gu, Hyo Shin Kwak, Du Hee Park, Hyo Soo Kim, Hyun Jai Cho, Ji Hyun Kim, Ju Young Kim, Kwang Min Park
-
Publication number: 20120214802Abstract: Described herein are novel beta-secretase inhibitors and methods for their use, including methods of treating Alzheimer's disease.Type: ApplicationFiled: October 9, 2009Publication date: August 23, 2012Inventors: Geoffrey M. Bilcer, Thippeswamy Devasamudram, Sudha V. Ankala, John C. Lilly, Chunfeng Liu, Hui Lei, Arun K. Ghosh, Makoto Inoue
-
Publication number: 20120202691Abstract: The invention relates to a compound of formula (I), which is suitable for use as a herbicide wherein G is hydrogen or an agriculturally acceptable metal, sulfonium, ammonium or latentiating group; Q is a unsubstituted or substituted C3-C8 saturated or mono-unsaturated heterocyclyl containing at least one heteroatom selected from O, N and S, or Q is heteroaryl or substituted heteroaryl; m is 1, 2 or 3; and Het is an optionally substituted monocyclic or bicyclic heteroaromatic ring; and wherein the compound is optionally an agronomically acceptable salt thereof.Type: ApplicationFiled: July 29, 2010Publication date: August 9, 2012Applicant: SYNGENTA CROP PROTECTION LLCInventors: Stephane André Marie Jeanmart, Adrian Longstaff, Christopher John Mathews, Claire Janet Russel, Russell Colin Viner, Frances Kathryn Wood
-
Publication number: 20120202852Abstract: The present invention is directed to heterocycle amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.Type: ApplicationFiled: October 25, 2010Publication date: August 9, 2012Inventors: James Barrow, Kelly-Ann Schlegel, Yoheng Shu, Zhi-Qiang Yang
-
Patent number: 8236991Abstract: The present invention relates to the purification of (2S,3S,5S)-5-amino-2-N,N-dibenzylamino-3-hydroxy-1,6-diphenylhexane (III) by making its crystalline acid addition salt, which can be used as such to produce Lopinavir/Ritonavir with high purity and yield.Type: GrantFiled: June 5, 2008Date of Patent: August 7, 2012Assignee: Aurobindo Pharma Ltd.Inventors: V Raghava Reddy Ambati, Srinivas Garaga, Ramesh Dandala, Sivakumaran Meenakshisunderam
-
Publication number: 20120196838Abstract: The invention relates to certain compounds according to Formula (I): or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders and immune disorders.Type: ApplicationFiled: January 25, 2012Publication date: August 2, 2012Applicant: Synta Pharmaceuticals Corp.Inventors: Jun Jiang, Junyi Zhang, Shoujun Chen, Lijun Sun
-
Publication number: 20120196884Abstract: The present invention relates to sulphonamide derivatives, whith a urea moiety. The invention also relates to the use of the derivatives as inhibitors of collagen receptor integrins, especially ?2?1 integrin inhibitors e.g. in connection with diseases and medical conditions that involve the action of cells and platelets expressing collagen receptors, their use as a medicament, e.g. for the treatment of thrombosis, inflammation, cancer and vascular diseases, pharmaceutical compositions containing them and a process for preparing them. The sulphonamide derivatives have the general formula (I) or (I?).Type: ApplicationFiled: June 14, 2010Publication date: August 2, 2012Applicant: BIOTIE THERAPIES CORPORATIONInventors: Jarkko Tapani Koivunen, Jani Korhonen, Anne Marjamäki, Liisa Nissinen, Marjo Pihlavisto, Olli Taneli Pentikäinen
-
Publication number: 20120197024Abstract: The present invention relates to a thiazole compound as a peroxisome proliferator activated receptor ? (PPAR?) activator or pharmaceutically acceptable salts thereof, and a pharmaceutical composition, a functional cosmetic composition, a health food, health beverages, a food additive and animal feeds containing the same.Type: ApplicationFiled: April 9, 2012Publication date: August 2, 2012Applicant: Seoul National University Industry FoundationInventors: Heonjoong KANG, Jae-Young KO, Hoo-Sang HWANG
-
Publication number: 20120178733Abstract: The present invention is directed to compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.Type: ApplicationFiled: August 19, 2011Publication date: July 12, 2012Inventors: Bing-Yan Zhu, Shawn M. Bauer, Zhaozhong J. Jia, Gary D. Probst, Yanchen Zhang, Robert M. Scarborough
-
Publication number: 20120164097Abstract: Bad odors on textile materials are often caused by body odor. The invention relates to a textile material treatment method for inhibiting body odor on textile materials, by which means the treated textiles, after having been worn, even after sweat-inducing sports activities, have a significantly reduced bad odor or even no odor. The invention also relates to a perfume composition and to a textile material treatment agent, respectively comprising urea derivatives and/or phenacylthiazolium salts, that counteract the formation of body odor.Type: ApplicationFiled: March 8, 2012Publication date: June 28, 2012Applicant: Henkel AG & Co. KGaAInventors: Ursula Huchel, Markus Egert, Andreas Bauer, Andreas Gerigk, Frank Pessel
-
Publication number: 20120157498Abstract: The present invention relates to novel substituted enaminocarbonyl compounds, to processes for their preparation and to their use for controlling animal pests, especially arthropods, in particular insects.Type: ApplicationFiled: December 22, 2011Publication date: June 21, 2012Applicant: Bayer CropScience AGInventors: Peter JESCHKE, Robert Velten, Thomas Schenke, Otto Schallner, Michael Edmund Beck, Rolf Pontzen, Olga Malsam, Udo Reckmann, Ralf Nauen, Ulrich Görgens, Leonard Pitta, Thomas Müller, Christian Arnold, Erich Sanwald
-
Patent number: 8193367Abstract: A new crystalline polymorph of ritonavir and methods for its use and preparation are disclosed.Type: GrantFiled: December 22, 2009Date of Patent: June 5, 2012Assignee: Abbott LaboratoriesInventors: John F. Bauer, Azita Saleki-Gerhardt, Bikshandarkoil A. Narayanan, Sanjay R. Chemburkar, Ketan M. Patel, Harry O. Spiwek, Philip E. Bauer, Kimberly A. Allen
-
Patent number: 8183383Abstract: PTP1B inhibitors with the following structure (formula I). Experiments indicate that these inhibitors can effectively inhibit the activity of protein tyrosine phosphatase 1B (PTP1B). They can be used as insulin sensitisers. They can be used to prevent, delay or treat diseases which are related to insulin antagonism mediated by PTP1B, especially diabetes type II and obesity. The invention also provides methods for preparing these inhibitors.Type: GrantFiled: February 26, 2008Date of Patent: May 22, 2012Assignee: Shanghai Institute of Materia Medica, Chinese Academy of SciencesInventors: Fajun Nan, Jia Li, Yi Wei, Wei Zhang, Jingya Li, Lei Shi
-
Publication number: 20120122918Abstract: Compounds of formula (1) have antibacterial activity: wherein R represents hydrogen or 1, 2 or 3 optional substituents; W is ?C(R1)—; R1 is hydrogen and R2 is hydrogen, methyl, or fluorine; or R1 and R2 taken together are —CH2—, —CH2CH2, —O—, or, in either orientation, —O—CH2— or —OCH2CH2—; and R3 is a radical of formula -(Alk1)m-(Z)p-(Alk2)-Q.Type: ApplicationFiled: November 28, 2011Publication date: May 17, 2012Applicant: BIOTA SCIENTIFIC MANAGEMENT PTY LTDInventors: David Ryall BROWN, Ian COLLINS, Lloyd George CZAPLEWSKI, David John HAYDON
-
Patent number: 8178566Abstract: The invention relates to new crystal forms of epothilone B.Type: GrantFiled: August 14, 2007Date of Patent: May 15, 2012Assignee: Novartis AGInventors: Ernst Küsters, Michael Mutz, Frank Stowasser
-
Patent number: 8178688Abstract: The present invention relates to novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same. The novel benzamidine derivatives of the present invention are useful for the prevention and treatment of osteoporosis, bone fractures and allergic inflammatory diseases.Type: GrantFiled: August 4, 2005Date of Patent: May 15, 2012Assignee: Dong Wha Pharmaceutical Co., Ltd.Inventors: Jin Soo Lee, Seok Hoon Ahn, Young Goo Jin, Sang Mi Jin, Whui-Jung Park, Sae Kwang Ku, Yun Ha Hwang, Pan Soo Kim, Sun Shin Yi, Jei Man Ryu
-
Publication number: 20120115811Abstract: Provided herein are compounds of formula I: wherein A, B, X, R1, R2 and subscript n are as defined in the following disclosure. Compositions comprising the compounds are also provided, as well as methods for their use, for example, in treatment of type 2 diabetes and type 2 diabetes-related conditions.Type: ApplicationFiled: February 12, 2010Publication date: May 10, 2012Applicant: Amgen Inc.Inventors: Xiaohui Du, Zice Fu, Jonathan B. Houze, Xian Yun Jiao, Yong-Jae Kim, Leping Li, Jinqian Liu, Mike Elias Lizarzaburu, Julio C. Medina, Wang Shen, Simon Turcotte, Ming Yu
-
Patent number: RE43596Abstract: ?- and ?-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.Type: GrantFiled: April 23, 2007Date of Patent: August 21, 2012Assignee: G.D. Searle LLCInventors: Michael L. Vazquez, Richard A. Mueller, John J. Talley, Daniel P. Getman, Gary A. DeCrescenzo, John N. Freskos, Robert M. Heintz, Deborah E. Bertenshaw